Evidera

There's still time to register for this expert webinar! » https://bit.ly/3wEFJta The world of drug development is evolving with the increased acceptance of real-world evidence (RWE). Disease registries, one of the most clinically rich sources of real-world data (RWD), are at the forefront of this change. These registries are purpose-built for research, allowing the collection of fit-for-purpose data, especially in rare diseases. Register for this expert webinar to gain insights into how RWE and RWD from registries enhance clinical development, approval and post-marketing analyses, particularly for rare diseases.

Attending #ASCO2024? Meet our real-world evidence experts in booth 10087: Epidemiology and Real-World Evidence: Firas Dabbous, PHD, MS Implementation Science (IS) Methods: Meredith Smith, PhD, MPA, FISPE Market Access Communications: Malinda O'Donnell, MSc Rare Disease and Cell and Gene Therapy: Elizabeth (Liz) Donahue, BSc Epidemiology and Real-World Data: Kelechi "Kacy" Emeanuru, MPH,CPH Direct-to-Provider Research: Mariah Baltezegar, MBA Evidence Synthesis: Heather Burnett, MSc Disease Modeling and Simulation: Hector Toro-Diaz, PhD, MSc, BSc #RWE #RWD #RWDE #oncologyexpertise

The world of drug development is evolving with the increased acceptance of real-world evidence (RWE). Stakeholders, such as regulatory agencies, health technology assessment bodies and payers, are acknowledging the value of RWE, paving the way for a new era in the industry. Disease registries, one of the most clinically rich sources of real-world data (RWD), are at the forefront of this change. These registries are purpose-built for research, allowing the collection of fit-for-purpose data, especially in rare diseases. Join Evidera and CorEvitas, LLC experts at our upcoming webinar that will focus on the evolving role of registry data in product development, approval and post-marketing value demonstration, as well as the advantages they offer. Register now! » https://bit.ly/3wEFJta

Today we celebrate #ClinicalTrialsDay and reflect on the progress of clinical research, acknowledging the modern data-driven environment we now contribute to and the benefits this ultimately brings to patient outcomes. We are proud to play our part, helping drug developers address the most challenging research questions. Learn more: https://bit.ly/3WM3ha5 #CTD2024

We were excited and honored to have Søren Eik Skovlund participate in the Patient Keynote today during Patients as Partners Europe in London. Understanding the perspectives and challenges of patients who want to participate in clinical trials is invaluable in the work we do to ensure patients are actively engaged and represented throughout the drug development process. Stop by booth 17 to speak with us about how we can partner with you on your patient engagement and insights strategy. #PatientsEU2024 #realworldevidence #patientcentricity

Are you attending Patients as Partners in London on May 14-15? Be sure to attend the Patient Keynote, where Søren Eik Skovlund will speak with a patient advocate and a pharma representative to discuss challenges patients face in clinical trial participation. Can’t make the keynote? Visit us at booth 17. Learn more about our patient-centered solutions or request a meeting. » https://bit.ly/4bClDhY

We were excited to see more than 115 attendees at our #ISPORAnnual #HEOR session, "Advancing the Use of Registry Data to Improve #HealthTechnologyAssessment and Payer Evidence." Stop by booth 619 to speak with the presenters or any of our experts on the growing use of #registrydata for #RWE generation and #valueassessment.

Find our team at booth 619 at #ISPORAnnual in Atlanta! Our experts have enjoyed making connections and discussing the latest in health economics, #healthtechnologyassessment, #realworldevidence, patient-reported outcomes and value assessment.

Check out this new white paper that elucidates the unique implementation of long-term follow-up studies in #cellandgenetherapies. #realworldevidence

Long-term follow-up studies are crucial for the success and efficacy of #cellandgenetherapies. However, optimizing these studies requires careful planning and strategic considerations. Learn more. » https://bit.ly/3w5kL6y